ReShape Lifesciences Inc. (RSLS)
Automate Your Wheel Strategy on RSLS
With Tiblio's Option Bot, you can configure your own wheel strategy including RSLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RSLS
- Rev/Share 15.5286
- Book/Share -0.4907
- PB -5.1964
- Debt/Equity -3.8221
- CurrentRatio 0.9204
- ROIC -9.1357
- MktCap 6084198.0
- FreeCF/Share -8.5867
- PFCF -1.3743
- PE -0.1844
- Debt/Assets 0.2018
- DivYield 0
- ROE -3.2398
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in the United Kingdom (UK) have been certified under the European Union (EU) Medical Device Regulation (MDR) (EU) 2017/745 and UK Conformity Assessment (UKCA), respectively.
Read More
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update.
Read More
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-25 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on May 9, 2025.
Read More
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device
Read More
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device Fully Compatible with Standard Implantable Pulse Generators, Enabling Cost-Effective Development IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/069,689, entitled, “High-Frequency Low Duty Cycle Patterns for Neural Regulation.
Read More
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS
Published: March 21, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ReShape Lifesciences Inc. (the “Company”) (NasdaqCM: RSLS) and Vyome Therapeutics, Inc. Under the terms of the Proposed Transaction, ReShape shareholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape's a.
Read More
About ReShape Lifesciences Inc. (RSLS)
- IPO Date 2016-10-06
- Website https://www.reshapelifesciences.com
- Industry Medical - Devices
- CEO Mr. Paul F. Hickey
- Employees 17